The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer
Open accessAbstract
BACKGROUND: The host inflammatory response has a vital role in carcinogenesis and tumour progression. We examined the prognostic value of inflammatory markers (albumin, white-cell count and its components, and platelets) in pre-treated patients with advanced renal cell carcinoma (RCC). METHODS: Using data from a randomised trial, multivariable proportional hazards models were generated to examine the impact of inflammatory markers and established prognostic factors (performance status, calcium, and haemoglobin) on overall survival (OS). We evaluated a new prognostic classification incorporating additional information from inflammatory markers. RESULTS: Of the 416 patients, 362 were included in the analysis. Elevated neutrophil counts, elevated platelet counts, and a high neutrophil-lymphocyte ratio were significant independent predictors for shorter OS in a model with established prognostic factors. The addition of inflammatory markers improves the discriminatory value of the prognostic classification as compared with established factors alone (C-statistic 0.673 vs 0.654, P=0.002 for the difference), with 25.8% (P=0.004) of patients more appropriately classified using the new classification. CONCLUSION: Markers of systemic inflammation contribute significantly to prognostic classification in addition to established factors for pre-treated patients with advanced RCC. Upon validation of these data in independent studies, stratification of patients using these markers in future clinical trials is recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Zahorec, R. (2001) · Bratislava Medical Journal · doi:10.1007/bf03656390 · Cited by 1,601
Cited by
Templeton, A. J., Ace, O., McNamara, M. G., Al-Mubarak, M., Vera-Badillo, F. E., Hermanns, T., Šeruga, B., Ocaña, A., Tannock, I. F., & Amir, E. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0146 · Cited by 719
Mei, Z., Shi, L., Wang, B., Yang, J., Xiao, Z., Du, P., Wang, Q., & Yang, W. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.005 · Cited by 304
Liu, X., Guan, G., Cui, X., Liu, Y., Liu, Y., & Luo, F. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s343110 · Cited by 105
The Prognostic Value of Platelet-to-Lymphocyte Ratio in Urological Cancers: A Meta-Analysis
Li, D.-Y., Hao, X.-Y., Ma, T.-M., Dai, H.-X., & Song, Y.-S. (2017) · Scientific Reports · doi:10.1038/s41598-017-15673-2 · Cited by 44
Metadata
- Authors
- Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V, De Souza, P., & Lee, C. K.
- Venue
- British Journal of Cancer
- Published
- 2013-06-18
- Volume
- 109
- Issue
- 1
- Pages
- 147-153
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2058615058
- Cited by
- 161
- References
- 3
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. https://app.cochat.ai/papers/10.1038/bjc.2013.300
- The paper
- Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V, De Souza, P., & Lee, C. K. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2013.300
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
